- Synthetic method of diphenhydrazide hydrochloride
-
The invention discloses a synthetic method of diphenhydrazide hydrochloride, and researches find that the yield of a diphenhydrazide hydrochloride crude product is more than 85% by using a mixed solvent of methyl tert-butyl ether and ethylene glycol dimethyl ether and adjusting specific parameters and an operation method of a production process at the same time. The purity of the crude diphenhydrazol hydrochloride product is greater than 98%. According to the method, the yield and quality of diphenhydrazide hydrochloride are greatly improved, the production is safer, and the industrializationis facilitated.
- -
-
Paragraph 0015-0019
(2020/11/22)
-
- Preparation method of benzhexol hydrochloride
-
The invention relates to the technical field of medicines, and concretely relates to a preparation method of a Parkinson disease treatment medicine benzhexol hydrochloride. The preparation method comprises the following steps: 1, adding tetrahydrofuran to a reaction bottle, adding magnesium chips, sequentially adding 5-10% of a bromoethane tetrahydrofuran solution, a solution A and a solution B into the reaction bottle in a dropwise manner while stirring, carrying out a heat insulation reaction after the dropwise addition is finished, and cooling; 2, adding piperidylpropiophenone hydrochloride, heating, carrying out a heat insulation reaction, distilling, and cooling after the distillation is finished; 3, adding a hydrochloric acid solution, heating and carrying out heat insulation after the addition, and cooling; and 4, filtering the above obtained mixture, washing the obtained filter cake by using water, and drying to obtain benzhexol hydrochloride.
- -
-
Paragraph 0018; 0019; 0083; 0084; 0085; 0086; 0087; 0088
(2016/11/28)
-
- Aryl-cycloalkyl-alkanolamines for treatment of neurotoxic injury
-
Compounds, compositions and methods of treatment are described to control brain damage associated with anoxia or ischemia which typically follows such conditions as stroke, cardiac arrest or perinatal asphyxia. The treatment includes administration of an aryl-cycloalkyl-alkanolamine compound as an antagonist to inhibit excitotoxic actions at major neuronal excitatory amino acid receptor sites.
- -
-
-
